Formulation: A crystalline solid
Formal Name: 3S,12S-bis(1,1-dimethylethyl)-8S-hydroxy-4,11-dioxo-9S-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-dimethyl ester
Purity: ≥95%
Formula Markup: C38H52N6O7
Formula Weight: 704,9
Shelf life (days): 1460
CAS Number: 198904-31-3
Notes: Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM).{24185} It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50 values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.{24184} Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.
English
Deutsch
